Intermittent reductions in respiratory neural activity elicit spinal

TNF-α-independent, atypical PKC-dependent inactivity-induced phrenic

motor facilitation

N.A. Baertsch and T.L. Baker-Herman

Department of Comparative Biosciences, University of Wisconsin-Madison, 2015 Linden Drive, Madison, WI 53706

Running title: Mechanisms initiating iPMF are pattern-dependent

Key words: inactivity, phrenic, plasticity, TNFα, atypical PKC

Corresponding author: Tracy Baker-Herman, PhD
Department of Comparative Biosciences
University of Wisconsin
2015 Linden Drive
Madison, WI
bakert@svm.vetmed.wisc.edu

Key Points Summary:

- Distinct mechanisms initiate iPMF following intermittent versus prolonged reductions in respiratory neural activity.
- Mechanisms of iPMF elicited by intermittent or prolonged reductions in respiratory neural activity converge on aPKC.
- Formation of long-lasting iPMF is pattern dependent.
- iPMF is associated with a proportional increase in phrenic respiratory-related dynamic range.
ABSTRACT

In many neural networks, mechanisms of compensatory plasticity respond to prolonged reductions in neural activity by increasing cellular excitability or synaptic strength. In the respiratory control system, a prolonged reduction in synaptic inputs to the phrenic motor pool elicits a TNFα- and atypical PKC-dependent form of spinal plasticity known as inactivity-induced phrenic motor facilitation (iPMF). Although iPMF may be elicited by a prolonged reduction in respiratory neural activity, iPMF is more efficiently induced when reduced respiratory neural activity (neural apnea) occurs intermittently. Mechanisms giving rise to iPMF following intermittent neural apnea are unknown. The purpose of this study was to test the hypothesis that iPMF following intermittent reductions in respiratory neural activity requires spinal TNFα- and aPKC. Phrenic motor output was recorded in anesthetized and ventilated rats exposed to brief intermittent (5, ~1.25 min), brief sustained (~6.25 min) or prolonged sustained (30 min) neural apnea. iPMF was elicited following brief intermittent and prolonged sustained neural apnea, but not following brief sustained neural apnea. Unlike iPMF following prolonged neural apnea, spinal TNFα was not required to initiate iPMF during intermittent neural apnea; however, aPKC was still required for its stabilization. These results suggest that different patterns of respiratory neural activity induce iPMF through distinct cellular mechanisms, but ultimately converge on a similar downstream pathway. Understanding the diverse cellular mechanisms that give rise to inactivity-induced respiratory plasticity may lead to development of novel therapeutic strategies to treat devastating respiratory control disorders when endogenous compensatory mechanisms fail.
**ABBREVIATIONS:** iPMF, inactivity-induced phrenic motor facilitation; TNFα, tumor necrosis factor alpha; aPKC, atypical protein kinase C; PKCζ, protein kinase C zeta; NMDAR, N-methyl D-aspartate receptor.
INTRODUCTION

An emerging principle of neuroscience is that prolonged perturbations in neural activity evoke compensatory mechanisms of plasticity that act to correct that perturbation (7, 26, 27, 40, 43); such “homeostatic plasticity” is thought to maintain neuronal activity within physiologically appropriate levels. Although mechanisms that stabilize neuronal activity levels in response to prolonged changes in neuronal activity have been relatively well studied in the cortex (41, 44) and hippocampus (9, 19), little is known regarding the role of on-going activity in shaping the output of neurons in the respiratory control system—a system in which preservation of neural activity is paramount. We recently demonstrated that a prolonged reduction in respiratory neural activity (i.e., a neural apnea), even in the absence of hypoxia or hypercapnia, elicits a rebound increase in phrenic motor output, a form of plasticity known as inactivity-induced phrenic motor facilitation (iPMF) (2, 4, 6, 21, 35, 36, 38). Mechanisms local to the phrenic motor pool sense and respond to reduced respiratory neural activity to give rise to iPMF since a unilateral withdrawal of spinal synaptic inputs to the phrenic motor pool (while maintaining brainstem and contralateral phrenic respiratory neural activity) elicits ipsilateral but not contralateral iPMF (35). Evidence indicates that iPMF consists of an early, transient phase that stabilizes into a long-lasting increase in phrenic motor output by a tumor necrosis factor alpha (TNFα)-induced increase in activation of an atypical protein kinase C (aPKC) isoform known as PKCζ (6, 38). However, mechanisms regulating the iPMF phenotype following prolonged neural apnea vary with genetic/epigenetic background since in some rat substrains iPMF is long-lasting (2, 6, 38), while in others phrenic amplitude is only transiently increased due to a NMDA
receptor-dependent constraint on the stabilization of long-lasting iPMF (36). While a physiological role for iPMF has not yet been directly shown, mechanisms allowing phrenic motor neurons to compensate for abnormal changes in activity may function to preserve an optimal level of activity, preventing catastrophic decreases in respiratory motor output (37).

Although it is rare to experience a single prolonged period of reduced respiratory neural activity, brief intermittent neural apneas are comparatively common during a variety of physiological and pathophysiological conditions that can occur throughout development and aging (37) such as apnea of prematurity (11), central sleep apnea (12, 15), and chronic heart failure (31). We recently demonstrated that brief intermittent disruptions in respiratory neural activity more efficiently induce iPMF than sustained patterns (2); however, cellular mechanisms giving rise to iPMF have only been investigated following a prolonged neural apnea. The purpose of this study was to test the hypothesis that intermittent neural apnea elicits long-lasting iPMF via spinal TNFα and aPKC-dependent mechanisms. Our results reveal that distinct mechanisms initiate and regulate expression of inactivity-induced phrenic plasticity in response to different patterns of reduced respiratory activity, but that similar downstream mechanisms function to stabilize it into its long-lasting form. An understanding of the diverse cellular mechanisms giving rise to inactivity-induced respiratory plasticity under varied stimulus patterns may lead to the development of novel treatment and/or prevention strategies for devastating respiratory control disorders associated with reduced respiratory neural activity, such as spinal cord injury (sustained) and central sleep apnea (intermittent) (37).
METHODS

Animals. Experiments were performed on 2.5-3.5 month old male Sprague-Dawley rats from Charles River (colony P09; n=62) Laboratories. Rats were housed 2 per cage with 12 hr light/dark cycles and food and water ad libitum. All experimental protocols were approved by the Animal Care and Use Committee at the University of Wisconsin, Madison.

Experimental Preparation. Isoflurane anesthesia was induced in a closed container and then continued on a nose cone with 2.5-3.5% isoflurane (50% O₂, N₂ balance) flowing from a vaporizer. Body temperature was monitored with a rectal thermometer (physitemp, model 700 1H) and maintained near 37.0°C with a custom heated surgery table. A tail vein catheter was placed for delivery of fluids (lactated Ringers solution; ~20% sodium bicarbonate as necessary) in order to maintain blood pressure and pH homeostasis throughout surgery and experimental protocols. The trachea was cannulated, and mechanical ventilation was begun (Model 683, Harvard Apparatus, Holliston Massachusetts; ~70 breaths/min, 2.5-3 ml; 50% O₂, N₂ balance). End-tidal CO₂ (ETCO₂) was measured continuously from the expired line of the ventilator circuit as an index of arterial pCO₂ with a flow-through capnograph (Capnogard, Respironics). In preliminary studies, we found that under our anesthesia protocol, spontaneously breathing rats typically have an ETCO₂ of ~45 mmHg. Thus, CO₂ was added to the inspired gas mix to maintain ETCO₂ near ~45 mmHg to avoid unintended neural apnea during mechanical ventilation. Tracheal pressure was monitored and inspired CO₂ was adjusted to ensure rats continued respiratory efforts throughout the surgery. The vagus nerve was isolated and cut bilaterally at the cervical level to prevent entrainment of respiratory frequency to
the ventilator. The right femoral artery was isolated and catheterized to monitor arterial blood pressure and draw blood samples (~0.3 ml) for pH and blood-gas analysis (ABL800; Radiometer, Copenhagen, Denmark). Rats were then transferred to urethane anesthesia (1 ml/100 g of 0.175 g/ml urethane infused at 6 ml/hr i.v.) and isoflurane was gradually withdrawn. Pressor responses to paw pad-pincho were tested to confirm adequate depth of anesthesia. The left phrenic nerve was dissected via a dorsal approach, cut distally, de-sheathed, placed on bipolar silver electrodes, and submerged in mineral oil. In some rats, a laminectomy was performed at cervical vertebrae 2 (C2), a small hole was cut in the dura, and a silicone catheter (2 French, Access Technologies) connected to a 50 µl syringe (Hamilton) was inserted into the intrathecal space and advanced caudally (~5 mm) to rest above spinal segment C4. Pancuronium bromide was infused (1 mg/kg, i.v.) to induce neuromuscular paralysis.

**Experimental Protocols.** At least one hour following termination of isoflurane anesthesia, “baseline” was established when phrenic nerve burst amplitude and frequency remained stable under isocapnic conditions for at least 15-20 min. An arterial blood sample was drawn to obtain baseline pCO₂, pO₂, and pH measurements (temperature corrected).

Rats were then exposed to one of three patterns of reduced respiratory neural activity: five brief intermittent neural apneas (~1.25 min each, separated by ~5 min; n=9), a single brief “massed” neural apnea of a similar cumulative duration (~6.25 min; n=9), or a single prolonged neural apnea (~30 min; n=9). A fourth group received a similar surgical preparation, but no neural apnea to account for any time-dependent changes in neural activity under isocapnic conditions (time controls, n=5). Neural apnea was induced by reducing inspired CO₂ until all rhythmic phrenic activity ceased (CO₂ apneic
threshold). In rats receiving brief intermittent neural apnea, inspired CO$_2$ was then immediately increased until respiratory neural activity resumed (CO$_2$ recruitment threshold) and baseline ETCO$_2$ was restored. In rats receiving brief massed or prolonged neural apnea, ETCO$_2$ was maintained ~2 mmHg below the CO$_2$ apneic threshold for 6 or 30 min, respectively, at which point neural apnea was reversed as described above. Importantly, in all cases arterial pO$_2$ was maintained with the ventilator during neural apnea. Arterial blood samples were drawn 5, 15, 30, and 60 min following neural apnea to confirm pCO$_2$ was within 1.5 mmHg of baseline and to allow maintenance of pO$_2$ and pH. At the end of each protocol, rats were exposed to a hypercapnic challenge (90 mmHg<ETCO$_2$<100 mmHg) to ensure observed results were not due to deterioration of the preparation or a lack of dynamic range in phrenic output.

Pharmacological Treatments. Separate groups of rats were exposed to brief intermittent neural apnea and intrathecal injection of the following pharmacological compounds: recombinant human soluble Tumor Necrosis Factor Receptor 1 (sTNFR1; R & D Systems), myristoylated ζ-pseudosubstrate inhibitory peptide (PKCζ-PS; Tocris Bioscience), and myristoylated scrambled ζ-pseudosubstrate peptide (scrPKCζ-PS; Tocris Bioscience). Solutions were prepared in artificial CSF (aCSF) (in mM: 120 NaCl, 3 KCl, 2 CaCl, 2 MgCl, 23 NaHCO$_3$, 10 glucose bubbled with 95% O$_2$/5% CO$_2$) and stored at -20°C. All solutions were delivered to the intrathecal space in 10 µl volumes at concentrations known to be sufficient to block iPMF induced by prolonged neural apnea (sTNFR1: 0.13 µg/µl) (6, 35, 36); (PKCζ-PS: 2 µg/µl) (35, 36, 38). Vehicle treated rats received 10 µl of aCSF. Rats were treated with sTNFR1 (n=6) or aCSF (n=6) 20-30 min prior to brief intermittent apnea, or PKCζ-PS (n=6) or scrPKCζ-PS (n=5) 5 min following
brief intermittent apnea. Separate groups of time control rats were also treated with intrathecal sTNFR1 (n=3) or PKCζ-PS (n=4) at corresponding time points to ensure there were no drug-dependent effects on baseline phrenic motor output.

Data Analysis. Phrenic burst activity was amplified (x10k), band-pass filtered (0.3-10 kHz; AM Systems), integrated (time constant 50 ms), and rectified. The resulting signal was digitized and analyzed with PowerLab (AD Instruments; Lab Chart 7.0 software). 60-breath bins were taken immediately prior to blood samples taken at baseline and 5, 15, 30, and 60 min post-neural apnea and analyzed for peak phrenic burst amplitude. Nerve burst amplitude was expressed as a percent change from baseline (% baseline). Statistical differences between groups and individual time points were determined using a two-way repeated measures ANOVA design and Bonferroni’s post-hoc tests, respectively. Group differences in maximum phrenic and hypoglossal amplitude elicited during hypercapnic challenge were determined using a one-way ANOVA and Tukey’s post hoc test. Linear regression analysis was used to determine the relationship of iPMF magnitude with the magnitude of the phrenic response to a hypercapnic challenge (Prism 6, Graph Pad software). A significance level of p<0.05 was used for all comparisons. All data are shown as means±SE.

RESULTS

Rat groups were organized into three experimental series (Table 1). In series #1, reduced respiratory neural activity was presented in three patterns: five brief neural apneas (~1.25 min each) separated by ~5 min of resumed respiratory neural activity (brief intermittent neural apnea), a single brief massed neural apnea of similar cumulative duration (~6.25
min), or a prolonged neural apnea (~30 min) that approximated the duration of the stimulus period (neural apneas plus intervening rest periods). The cumulative duration of brief intermittent neural apnea (6:14 ± 0:25 min:sec) was not significantly different than the duration of brief massed neural apnea (6:23 ± 0:20 min:sec; p>0.05), nor was the total stimulus period of brief intermittent neural apnea (28:01 ± 1:04 min:sec) different than the duration of prolonged neural apnea (28:46 ± 0:31 min:sec; p>0.05). In series #2, the cumulative duration and total stimulus period of brief intermittent neural apnea was not significantly different between groups receiving sTNFR1 (7:02 ± 0:33 and 31:11 ± 2:06 min:sec, respectively) or aCSF (5:25 ± 24 and 30:59 ± 2:46 min:sec, respectively; p>0.05). Similarly, in series #3 the cumulative duration and total stimulus period of brief intermittent neural apnea was not significantly different between groups receiving PKCζ-PS (5:45 ± 0:30 and 29:16 ± 0:58 min:sec, respectively) or scrPKCζ-PS (6:36 ± 0:58 and 28:45 ± 1:13 min:sec, respectively; p>0.05).

Table 1 shows PaCO₂, PaO₂, pH, and mean arterial pressure (MAP) during baseline and 60 min post-neural apnea. Average PaCO₂, PaO₂, pH and MAP were not significantly different at any time point when compared across treatment groups (p>0.05). There were no time-dependent changes in PaCO₂ or pH from baseline to 60 min post neural apnea within any treatment group (p>0.05). In some groups we observed a small but significant decrease in PaO₂ and/or MAP from baseline to 60 min. However, these changes were not considered to have contributed to our results since 1) changes were small and inconsistent, 2) PaO₂ was maintained well above levels that stimulate breathing (>200 mmHg), 3) small changes in MAP (~20 mmHg) do not significantly alter phrenic motor output in rats (42), and 4) other rat groups and previous studies have
demonstrated similar iPMF without changes in PaO$_2$ (2, 6, 38) or MAP (21).

Series #1: Intermittent neural apnea elicits long-lasting iPMF.

We utilized a rat substrain in which spinal NMDA receptor activation during transient iPMF restrains stabilization of long-lasting iPMF following prolonged neural apnea (36); thus, we sought to determine if a similar NMDA receptor-mediated constraint was operative following intermittent neural apnea. Representative compressed phrenic neurograms from prolonged, brief intermittent, and brief massed neural apnea and time control groups are shown in Figure 1A. Average changes in phrenic burst amplitude are shown in Figure 1B. In time control rats, there were no changes in phrenic burst amplitude from baseline at any time point (5 min: -1±5, 15 min: 4±4, 30 min: 6±3, 60 min: 9±3, %baseline; p>0.05), suggesting that our preparation was stable during the recording period. A brief sustained neural apnea was not sufficient to elicit iPMF since phrenic amplitude was not different from time controls at any time-point following neural apnea (5 min: -3±5, 15 min: 2±4, 30 min: -1±4, 60 min: 6±4, %baseline; p>0.05). However, when the sustained neural apnea was prolonged, phrenic burst amplitude was initially increased relative to time controls and rats exposed to brief massed neural apnea (5 min: 52±10, 15 min: 43±9, %baseline; p<0.05), but progressively decayed by 30 (31±7, %baseline) and 60 min (19±5, %baseline) such that phrenic amplitude was no longer significantly different from either group (p>0.05); confirming that iPMF is transient in this substrain when NMDA receptors are not blocked during early iPMF (36). By contrast, rats exposed to intermittent neural apnea expressed a long-lasting increase in phrenic burst amplitude upon resumption of respiratory neural activity (5 min: 60±9, 15 min: 73±11, 30 min: 67±12, 60 min: 71±11, %baseline) that was significantly different
from time controls (p<0.0001) and brief sustained neural apnea (p<0.0001) at all time points, and prolonged neural apnea at 30 and 60 min (p<0.05). Collectively, these data indicate that brief repeated episodes of neural apnea elicit long-lasting iPMF without the necessity for spinal NMDA receptor inhibition.

At the end of each protocol (60 min), rats were exposed to a severe hypercapnic challenge to determine if expression of inactivity-induced plasticity resulted in an increase in phrenic dynamic range (i.e. greater maximum amplitude). The average maximum phrenic response to hypercapnia is shown in Figure 1C. As expected, all rats (including time controls) expressed a significant increase in phrenic burst amplitude from baseline in response to hypercapnia (p<0.05). The maximum phrenic burst amplitude elicited 60 min following prolonged (102±15 %baseline) and brief massed (70±5 %baseline) neural apnea (treatments which did not induce long-lasting iPMF) were not significantly different from the response in time controls (74±9 %baseline; p>0.05). However, 60 min following brief intermittent neural apnea, when iPMF was expressed, the maximum phrenic amplitude during hypercapnia was significantly increased compared to all other groups (173±30 %baseline; p<0.05). Figure 1D illustrates the relationship between iPMF and phrenic burst amplitude response to hypercapnia. 60 min following brief intermittent neural apnea, there was a significant linear relationship between the magnitude of iPMF and phrenic burst amplitude during hypercapnia (p=0.005; R²=0.699). Although prolonged neural apnea elicited only a transient iPMF (due to NMDA receptor-mediated constraint of long-lasting iPMF; 36) and did not increase the phrenic hypercapnic response on average, a few individual rats continued to express a small amount of iPMF at 60 min which was associated with an elevated phrenic
burst amplitude response to hypercapnia (p=0.002; $R^2=0.756$). However, changes in phrenic amplitude 60 min following brief massed neural apnea did not have significant relationship with the phrenic amplitude during hypercapnia (p=0.940; $R^2=0.001$, respectively). Similarly, there was not a significant relationship among time controls (p=0.478; $R^2=0.071$). Thus, expression of iPMF following intermittent neural apnea is associated with a proportional increase in respiratory-related phrenic dynamic range.

Series #2: iPMF following intermittent neural apnea does not require spinal TNFα

Since spinal TNFα is required for long-lasting iPMF following a prolonged neural apnea, we sought to determine if TNFα is similarly required for iPMF following brief intermittent neural apnea. Representative compressed phrenic neurograms from rats receiving aCSF or a TNFα scavenger (sTNFR1) 15-20 min prior to brief intermittent neural apnea or at the corresponding time point in time controls is shown in Figure 2A. Average changes in phrenic burst amplitude are shown in Figure 2B. In time controls, intrathecal sTNFR1 did not change phrenic amplitude at any time point (5 min: 7±4, 15 min: 3±4, 30 min: 4±15, 60 min: 2±2, %baseline) compared to baseline (p>0.05). In rats receiving intrathecal vehicle (aCSF) prior to intermittent neural apnea, phrenic burst amplitude was significantly increased from time controls at all time points post neural apnea (5 min: 55±6, 15 min: 61±7, 30 min: 64±6, 60 min: 54±5, %baseline; p<0.001), indicating long-lasting iPMF. Treatment with intrathecal sTNFR1 prior to brief intermittent neural apnea did not impair iPMF since, similar to rats receiving aCSF, phrenic burst amplitude was significantly increased from time controls at all time points post-neural apnea (5 min: 51±5, 15 min: 69±6, 30 min: 69±6, 60 min: 71±8; p<0.001). Indeed, there were no significant differences in phrenic burst amplitude between rats
receiving intrathecal aCSF or sTNFR1 prior to brief intermittent neural apnea (p>0.05),
indicating that spinal TNFα signaling is not required for iPMF following brief
intermittent neural apnea.

Series #3: iPMF following intermittent neural apnea requires spinal aPKC

To test the hypothesis that stabilization of iPMF following brief intermittent neural apnea
requires spinal aPKC activity, rats were treated with intrathecal scrPKCζ-PS or PKCζ-PS
~10 min following brief intermittent neural apnea or at the corresponding time point in
time controls. Representative compressed phrenic neurograms are shown in Figure 3A.
Average change in phrenic nerve burst amplitude are shown in Figure 3B. In time
controls, intrathecal PKCζ-PS had no effect on phrenic burst amplitude (15 min: 8±4, 30
min: 17±12, 60 min: 11±10), when compared to pre-drug levels (5 min: 2±7; p>0.05) and
baseline (p>0.05). In rats receiving intrathecal scrPKCζ-PS following brief intermittent
neural apnea, phrenic burst amplitude was significantly increased from time controls at
all time points post neural apnea (5 min: 62±10, 15 min: 62±11, 30 min: 66±10, 60 min:
76±10, %baseline; p<0.001), indicating scrPKCζ-PS did not impair iPMF. Rats receiving
intrathecal PKCζ-PS expressed significant increases in phrenic burst amplitude prior to (5
min: 53±7 %baseline) and immediately following (15 min: 49±5 %baseline) delivery of
PKCζ-PS, when compared to time controls (p<0.001), indicating iPMF. However, shortly
after PKCζ-PS delivery, phrenic burst amplitude began to gradually decline such that by
30 (26±4 %baseline) and 60 (6±6 %baseline) min, phrenic burst amplitude was
significantly decreased compared to rats receiving scrPKCζ-PS (p<0.01) and no longer
different from time controls (p>0.05), indicating iPMF had been abolished. These data
indicate that spinal aPKC is necessary for iPMF following brief intermittent neural apnea.

**DISCUSSION**

Although inactivity-induced phrenic motor facilitation was only recently described (21), we are beginning to grasp its underlying mechanisms. Our working model suggests that iPMF following prolonged neural apnea requires a spinal TNFα-induced increase in aPKC activity to stabilize a transient increase in phrenic burst amplitude into long-lasting iPMF (6, 38); stabilization of long-lasting iPMF may be disrupted by NMDAR activation during transient iPMF expression, at least in some rat substrains (36).

Here, we tested the hypothesis that similar TNFα- and aPKC-dependent mechanisms give rise to iPMF following brief intermittent neural apnea. Contrary to our hypothesis, we found that iPMF following intermittent neural apnea does not require TNFα, but retains its requirement for aPKC. Further, we show that unlike iPMF following prolonged neural apnea (36), stabilization of iPMF following brief intermittent reductions in respiratory neural activity does not require NMDAR inhibition. We conclude that distinct cellular processes initiate and regulate iPMF expression following different patterns of reduced respiratory neural activity that then converge on a similar downstream mechanism. Heterogeneous mechanisms giving rise to iPMF may increase system flexibility and ensure that the phrenic motor system responds appropriately during conditions that result in different patterns of reduced respiratory neural activity.

**Distinct mechanisms give rise to iPMF following intermittent versus prolonged reductions in respiratory neural activity.**

Although typically thought of as a pro-inflammatory cytokine, TNFα also plays
an important role in the healthy CNS and has been shown to play a key role in neuronal homeostatic responses to prolonged activity deprivation (5, 6, 26, 34). For example, in cultured hippocampal neurons, a prolonged reduction in neural activity induces a TNFα-dependent increase in AMPA receptor membrane expression and synaptic transmission *in vitro* (5, 34); further, TNFα is necessary for scaling up of visual cortical neurons responses following monocular deprivation *in vivo* (18). Glia are likely the source of diffusible TNFα which is released, presumably in response to low extracellular glutamate levels caused by reduced network activity, to initiate a compensatory increase in synaptic strength (26, 34). Similarly, multiple studies from our laboratory have demonstrated a necessary role for TNFα in iPMF following a prolonged neural apnea (6, 35, 36). Although greater than 24 hrs of activity deprivation is typically required to elicit TNFα-dependent plasticity in the hippocampus (34) and visual cortex (18), a sustained reduction in the activity of the phrenic motor pool induces TNFα-dependent iPMF relatively rapidly (~30 min) (6, 35, 36). Indeed, a rapid response to reduced activity of the phrenic neural network may be appropriate given the life-threatening consequences of a loss of phrenic motor output. Thus, we hypothesize that a prolonged duration of reduced respiratory neural activity within the phrenic motor nucleus is sensed by nearby glia and responded to through the release of diffusible TNFα and initiation of an aPKC-dependent signaling cascade within phrenic motor neurons, giving rise to iPMF.

In this study, we show that spinal TNFα is not required for iPMF elicited by brief intermittent episodes of reduced respiratory neural activity. These pattern-specific differences in the initiation of iPMF may reflect the existence of two different types of plasticity utilizing different “sensors” of reduced neural activity. For example, reducing
the activity of single cortical neurons with focal application of TTX in vitro induces a relatively rapid (1-2 hrs) scaling up of synaptic strength that does not likely involve TNFα release, but requires reduced neuronal spiking and intracellular Ca\(^{2+}\) levels (14). Thus, in addition to TNFα-dependent homeostatic regulation of network activity, mechanisms intrinsic to neurons may allow relatively rapid adjustments in the activity of individual cells (26). Moreover, the expression of TNFα-dependent homeostatic plasticity in the visual cortex transitions to a TNFα-independent and CamKII-dependent mechanism during adulthood in some mouse substrains (29), demonstrating that multiple mechanisms can elicit a phenotypically similar response to reduced neural activity. Cellular cascades initiating iPMF following brief intermittent neural apnea are currently unknown.

**Mechanisms of iPMF elicited by different patterns of inactivity converge on aPKC**

Despite utilizing different mechanisms of induction, spinal aPKC activity is necessary for iPMF elicited by both brief intermittent and prolonged neural apnea. Specifically, spinal aPKC activity is necessary during the early phase of iPMF since intrathecal delivery of the aPKC inhibitor PKCζ-PS abolishes iPMF when delivered shortly (~10 min) following the resumption of respiratory neural activity (Results presented here; 38). Therefore, we speculate that this shared requirement for aPKC during the formation and stabilization of iPMF represents a “convergence” on similar downstream cellular machinery that ultimately gives rise to the iPMF phenotype. This type of convergence between distinct mechanisms of plasticity is not uncommon since different forms of homoeostatic plasticity can involve conserved cellular cascades. For example, Beta-3 integrin is thought to be a point of convergence between TNFα-
dependent synaptic scaling and other forms of homeostatic synaptic scaling with shorter
time-courses in hippocampal neurons (1). Further, other well-studied effectors of synaptic
plasticity (e.g. BDNF, MSK1, and MAPK) have been implicated in both homeostatic (i.e.
activity-dependent) and adaptive (i.e. experience-dependent) plasticity elicited in
response to different types of stimuli (8). Moreover, a similar convergence on aPKC
among mechanisms of plasticity with different modes of induction has been observed in
other highly active oscillatory systems. For example, in the pacemaker nucleus of weakly
electric fish, aPKC is required for both the regulation of a basal “set point” to maintain
stable neural activity as well as adaptive, experience-dependent, plasticity in response to
social interaction (13). Interestingly, protein phosphatases regulated by Ca\(^{2+}\) influx
(calcineurin) determine the duration of this plasticity (13), perhaps similar to the
NMDAR mediated constraint on iPMF following prolonged neural apnea. Thus, we
suspect that iPMF elicited by sustained and brief intermittent reductions in respiratory
neural activity utilize conserved downstream mechanisms that are subject to different
regulatory constraints.

Our observation that long-lasting, but not transient, iPMF is associated with an
enhanced phrenic response during a hypercapnic challenge is consistent with previous
reports (2, 35, 36). Indeed, the phrenic hypercapnic response is also enhanced following
prolonged neural apnea under conditions of NMDA receptor inhibition in this rat
substrain (36). Similar shifts in the phrenic hypercapnic response may suggest that
mechanisms downstream from aPKC that ultimately give rise to long-lasting iPMF are
similar, independent of how iPMF is induced. However, we can not rule out that the
signaling pathways underlying iPMF elicited by different patterns of neural apnea
diverge and become distinct once again downstream of aPKC. For example, TNF-receptor activation can lead to the interaction of aPKC with its scaffolding protein SQSTM1/p62, which can then initiate the NF-kappaB cascade to increase transcription of inflammatory and cell survival genes (24, 32, 33). Also, TNF receptor associated factor 6 (TRAF6) can induce SQSTM1/p62-dependent membrane receptor internalization and degradation (24), which likely involves interactions with aPKC. And, in a hippocampal LTP paradigm, aPKC interactions with SQSTM1/p62 are required for AMPAR trafficking to the membrane and expression of LTP (16). Therefore, different inducing stimuli can activate cellular mechanisms involving aPKC, which then diverge through directed and selective protein-protein interactions. Studies investigating the cellular mechanisms downstream of aPKC will be necessary to determine whether similar processes underlie the maintenance of iPMF elicited by different patterns of reduced respiratory neural activity.

Regulation of iPMF is pattern dependent

Similar to other forms of respiratory neuroplasticity (3, 10), iPMF is pattern sensitive, and the degree of sensitivity appears to be subject to genetic/epigenetic differences (2, 36). While iPMF is not expressed following a brief massed neural apnea, iPMF may be revealed if the duration of the massed neural apnea is broken up into several shorter episodes (2). Interestingly, in rat substrains that lack the NMDA receptor-dependent regulatory constraint on iPMF, this sensitivity to pattern may be overcome if the duration of neural apnea is prolonged, resulting in robust long-lasting iPMF (2, 38). However, prolonged neural apnea only revealed a transient increase in phrenic motor output in the rat substrain examined in this study due to a NMDA receptor-dependent
regulatory constraint on the stabilization of long-lasting iPMF (36). In contrast to the transient iPMF observed following prolonged neural apnea, intermittent neural apnea elicited a robust and long-lasting iPMF, suggesting similar regulatory mechanisms do not constrain iPMF when respiratory neural activity is reduced intermittently. Thus, an important question is: why does spinal NMDA receptor activation restrain iPMF following a prolonged episode of reduced neural activity but not following intermittent episodes? One possibility is that periods of restored activity between intermittent neural apneas desensitize NMDA receptors, diminishing their regulatory effect during the stabilization of iPMF. Indeed, NMDARs can be desensitized rapidly by stimuli such as excessive NMDAR activation, hyperactivity and increased intracellular Ca\(^{2+}\), altered activity of intracellular kinases and/or phosphatases, and G-protein coupled receptor (GPCR) activation (17, 20, 22, 23, 28, 30, 39), and a greater desensitization is often observed following repeated stimulation (25). Alternatively, mechanisms downstream of NMDA receptor activation may lead to the differential regulation of iPMF following distinct patterns of reduced respiratory neural activity. Further investigation of the mechanisms regulating the expression of iPMF will be necessary to understand how they are affected by the pattern of reduced respiratory neural activity.

**Perspectives and Significance**

We are beginning to appreciate that mechanisms local to the phrenic motor pool respond vigorously and rapidly to reductions in neural activity— without changes in blood gases (4, 35, 37). Importantly, complete absence of phrenic neural activity is not necessary for iPMF to be induced (35). As such, iPMF may represent a mechanism of “homeostatic” or compensatory plasticity that enables phrenic motor neurons to adapt to
changes in neuronal excitability and/or synaptic inputs that may occur throughout life, thereby preventing catastrophic decreases in phrenic motor output. Data presented here suggest that the phrenic motor pool can initiate and regulate compensatory responses to different patterns of reduced respiratory neural activity through distinct mechanisms, a characteristic which may lead to increased system flexibility and allow adaptation to physiological and pathological conditions associated with heterogeneous manifestations of reduced respiratory neural activity (37). Although we are beginning to grasp the underlying mechanisms of iPMF elicited by different patterns of reduced respiratory neural activity and under varied genetic/epigenetic contexts, the robustness and physiological significance of this plasticity during pathological conditions associated with reduced activity of respiratory motor pools in a highly variable human population remains unknown. Future studies investigating inactivity-induced respiratory plasticity under such conditions may lead to the development of novel therapeutic strategies for when these endogenous mechanisms of compensatory plasticity fail.

Acknowledgements: Research support was provided by the National Heart, Lung and Blood Institute (NHLBI), grant number HL105511.
REFERENCES:


FIGURE LEGENDS:

**Figure 1**: Long-lasting iPMF is pattern dependent in CRSD rats. A. Representative compressed phrenic neurograms depicting integrated nerve burst amplitude before (baseline), during, and for 60 min following either brief intermittent, brief massed, or prolonged neural apnea, or an equivalent duration in time controls (top to bottom, respectively). B. Mean changes in phrenic burst amplitude (%baseline) 5, 15, 30, and 60 min following brief intermittent (●), brief massed (■), prolonged (▲), or no neural apnea (time controls; ▼). C. Average phrenic burst amplitude responses to hypercapnic challenge 60 min post neural apnea. Shaded bar indicates significant long-lasting iPMF was expressed. D. Linear regression comparing the magnitude of iPMF 60 min post neural apnea to the maximum phrenic amplitude elicited during a subsequent hypercapnic challenge, indicating iPMF is associated with a proportional increase in respiratory related phrenic dynamic range. *significantly different from time control; # significantly different from brief massed neural apnea; #significantly different from prolonged neural apnea; p<0.05.

**Figure 2**: iPMF following brief intermittent neural apnea does not require spinal TNFα. A. Representative compressed phrenic neurograms from rats receiving intrathecal vehicle (aCSF, top) or sTNFR1 (middle) ~15 min prior to brief intermittent neural apnea, and intrathecal sTNFR1 in a rat receiving no neural apnea (time control, bottom). B. Mean changes in phrenic burst amplitude (%baseline) 5, 15, 30 and 60 min following brief intermittent neural apnea in rats receiving intrathecal sTNFR1 (●) or aCSF (■), and at equivalent time-points in time control rats receiving intrathecal sTNFR1 (▼). *significantly different from sTNFR1 time controls.; p<0.05.

**Figure 3**: Spinal aPKC is necessary for iPMF elicited by brief intermittent neural apnea. A. Representative compressed phrenic neurograms from rats receiving intrathecal injection of a scrambled control peptide (scrPKCζ-PS, top) or PKCζ-PS (middle) ~10 min following brief intermittent neural apnea, and intrathecal PKCζ-PS in a rat receiving no neural apnea (time control, bottom). B. Mean changes in phrenic burst amplitude (%baseline) 5, 15, 30 and 60 min following brief intermittent neural apnea in rats receiving intrathecal PKCζ-PS (●) or scrPKCζ-PS (■), and at equivalent time-points in time control rats receiving intrathecal PKCζ-PS (▼). *significantly different from PKCζ-PS time controls; #significantly different from brief intermittent neural apnea and scrPKCζ-PS p<0.05.
<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Time</th>
<th>PaCO₂</th>
<th>PaO₂</th>
<th>pH</th>
<th>MAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brief Intermittent (n=9)</td>
<td>Baseline</td>
<td>49 ± 1</td>
<td>282 ± 5</td>
<td>7.34 ± 0.01</td>
<td>127 ± 6</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>49 ± 1</td>
<td>267 ± 7*</td>
<td>7.33 ± 0.01</td>
<td>98 ± 7*</td>
</tr>
<tr>
<td>Brief Massed (n=9)</td>
<td>Baseline</td>
<td>48 ± 1</td>
<td>291 ± 5</td>
<td>7.35 ± 0.01</td>
<td>114 ± 7</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>48 ± 1</td>
<td>286 ± 6</td>
<td>7.35 ± 0.01</td>
<td>108 ± 3</td>
</tr>
<tr>
<td>Prolonged (n=9)</td>
<td>Baseline</td>
<td>47 ± 2</td>
<td>281 ± 3</td>
<td>7.36 ± 0.01</td>
<td>111 ± 5</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>47 ± 1</td>
<td>269 ± 7</td>
<td>7.35 ± 0.01</td>
<td>98 ± 2</td>
</tr>
<tr>
<td>Time Control (n=5)</td>
<td>Baseline</td>
<td>47 ± 1</td>
<td>292 ± 10</td>
<td>7.36 ± 0.01</td>
<td>111 ± 9</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>47 ± 1</td>
<td>264 ± 11*</td>
<td>7.36 ± 0.01</td>
<td>93 ± 11*</td>
</tr>
</tbody>
</table>

Series #2: Spinal TNFα is not necessary

<table>
<thead>
<tr>
<th></th>
<th>Time</th>
<th>PaCO₂</th>
<th>PaO₂</th>
<th>pH</th>
<th>MAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>sTNFR1 + Brief Intermittent (n=6)</td>
<td>Baseline</td>
<td>46 ± 1</td>
<td>292 ±4</td>
<td>7.37 ± 0.01</td>
<td>108 ± 4</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>46 ± 1</td>
<td>285 ± 7</td>
<td>7.35 ± 0.01</td>
<td>92 ± 8*</td>
</tr>
<tr>
<td>aCSF + Brief Intermittent (n=6)</td>
<td>Baseline</td>
<td>46 ± 1</td>
<td>274 ± 5</td>
<td>7.37 ± 0.01</td>
<td>93 ± 3</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>46 ± 1</td>
<td>262 ± 7</td>
<td>7.36 ± 0.02</td>
<td>85 ± 6</td>
</tr>
<tr>
<td>sTNFR1 + Time Control (n=3)</td>
<td>Baseline</td>
<td>45 ± 2</td>
<td>286 ± 3</td>
<td>7.36 ± 0.02</td>
<td>91 ± 6</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>45 ± 2</td>
<td>271 ± 5</td>
<td>7.38 ± 0.00</td>
<td>99 ± 4</td>
</tr>
</tbody>
</table>

Series #3: Spinal aPKC is necessary

<table>
<thead>
<tr>
<th></th>
<th>Time</th>
<th>PaCO₂</th>
<th>PaO₂</th>
<th>pH</th>
<th>MAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brief Intermittent + PKCζ-PS (n=6)</td>
<td>Baseline</td>
<td>45 ± 1</td>
<td>267 ± 3</td>
<td>7.35 ± 0.01</td>
<td>110 ± 8</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>45 ± 1</td>
<td>251 ±4*</td>
<td>7.37 ± 0.01</td>
<td>86 ± 11*</td>
</tr>
<tr>
<td>Brief Intermittent + scrPKCζ-PS (n=5)</td>
<td>Baseline</td>
<td>47 ± 1</td>
<td>273 ± 6</td>
<td>7.35 ± 0.02</td>
<td>121 ± 13</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>47 ± 1</td>
<td>250 ± 4*</td>
<td>7.32 ± 0.02</td>
<td>104 ± 11</td>
</tr>
<tr>
<td>Time Control + PKCζ-PS (n=4)</td>
<td>Baseline</td>
<td>48 ± 0</td>
<td>285 ± 8</td>
<td>7.35 ± 0.01</td>
<td>124 ± 4</td>
</tr>
<tr>
<td></td>
<td>60 min</td>
<td>48 ± 1</td>
<td>267 ± 18</td>
<td>7.36 ± 0.00</td>
<td>97 ± 8*</td>
</tr>
</tbody>
</table>

Table 1. Arterial PO₂ (in mmHg), PCO₂ (in mmHg), pH, and mean arterial pressure (MAP) at baseline and 60 min following treatment in all rat groups. Data are presented as means ± SE. No significant differences in any variable were detected at any time point between groups. *significantly different than baseline; p<0.05.